Palvella Therapeutics, Inc.
NASDAQPalvella Therapeutics has given back the gains that made last week's bullish thesis look prescient — down 11% on the week to $104.67 — and the question now is whether the stubborn short base is finally being vindicated. The reversal is sharp but the positioning picture has not resolved. Short interest edged down 6.6% over the week to 17.4% of free float, trimming from the higher…
Snapshot as of 5 Jul 2026
Palvella Therapeutics has given back the gains that made last week's bullish thesis look prescient — down 11% on the week to $104.67 — and the question now is whether the stubborn short base is finally being…
Palvella Therapeutics heads into June with the bullish options thesis from last week looking increasingly vindicated: the stock has added 7.7% on the week to $117.59, and the call-heavy positioning that defined the…
Palvella Therapeutics enters the week with a sharp split between options sentiment and short positioning — calls dominating the tape while nearly a fifth of the float remains borrowed against the stock. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PVLA — free to start on ORTEX.
Sign up for free →Open PVLA on ORTEX